Navigation Links
InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
Date:12/10/2008

BRISBANE, Calif., Dec. 10 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today said that it will report top-line results in January 2009 from its Phase 1b clinical trial of protease inhibitor ITMN-191 (R7227) in combination with standard-of-care Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin) for 14 days of treatment in treatment-naive patients chronically infected with the hepatitis C virus (HCV) genotype 1. ITMN-191 is being developed in collaboration with Roche.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "We now expect to report top-line data from six dosage cohorts; three cohorts each of twice-daily and three-times-daily regimens. Although the 14-day triple combination study remains blinded at this time, and thus only limited inferences regarding safety can be made, adverse events to date have generally been mild to moderate and there have been no discontinuations during the study. Results from this study have guided the design of our planned Phase 2 program which is anticipated to begin in the first half of 2009."

Mr. Welch continued, "In addition, we are pleased to report that the first dosage cohort has been enrolled in the INFORM-1 study of ITMN-191 in combination with polymerase inhibitor R7128 (Roche/Pharmasset). INFORM-1 is the first ever study to investigate the combined effects of two direct antiviral agents in the absence of interferon in treatment-naive HCV patients. We expect results of this study to be reported at a major medical conference in the first half of 2009."

Phase 1b Triple Combination Trial Design

The Phase 1b randomized, double-blind, placebo-controlled, 14-day triple combination study in treatment-naive patients chronically infected with HCV genotype 1 was designed to inform the dose selection and study de
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. Spherix Reports Second Quarter Earnings
11. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014  Publicis Groupe customer engagement agency ... and Healthcare Industry Group Leader, has been featured in ... most inspiring people in the life-sciences industry. Those chosen ... development, marketing, technology, creativity, strategy and medicine. ... partner in its leading Rosetta Consulting practice. In 2012, ...
(Date:8/21/2014)... Aug. 21, 2014  Decision Resources Group finds ... Brazil and ... and commonly prescribe long-acting beta-agonist (LABA)- and long-acting ... so within current severe cost/coverage constraints. Therefore, new ... expected to launch in these countries—which will considerably ...
(Date:8/21/2014)... 21, 2014 /PRNewswire-iReach/ -- ScriptPro has been certified ... its Common Security Framework (CSF). According to ... Manager, "We appreciate this rigorous, top-to-bottom audit. Security-minded ... this certification signifies. Our business partners need to ... CSF CERTIFICATION PROCESS: ScriptPro,s internal security processes and ...
Breaking Medicine Technology:Shannon Hartley Shines in PharmaVOICE 100 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3ScriptPro Achieves HITRUST Certification 2
... Johnson & Johnson (NYSE: JNJ ) today ... & Diagnostics (MD&D) and Sheri McCoy, currently Worldwide Chairman, ... Committee and join William C. Weldon, Chairman of the ... of the Chairman.  Both appointments are effective January 3, ...
... LAKE FOREST, Ill., Dec. 15, 2010 RoundTable ... focused exclusively on the healthcare industry, announced today ... to sell one of its portfolio companies, Clinical ... private investment firm representing Pritzker family interests.  Terms ...
Cached Medicine Technology:Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee 2Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee 3RoundTable Healthcare Partners Announces Sale of Clinical Innovations, LLC to The Pritzker Group 2
(Date:8/22/2014)... growth factor receptor (EGFR) mutations found in the circulating ... non-small cell lung cancer (NSCLC) patients correlates well with ... EGFR tyrosine kinase inhibitor (TKI) therapy is approved for ... the standard for determining mutation status is with DNA ... or not available. A more abundant and less invasive ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Advancements ... for some clinical applications due to their cost-effectiveness, ... emerging innovations in ultrasound, such as the evolution ... expected to keep the market moving throughout 2014 ... mobility can enhance not only the point-of-care (POC) ...
(Date:8/22/2014)... August 22, 2014 CarePoint Health ... in Internal Medicine, Geriatrics, Hospice and Palliative Care, ... Health Medical Group. Their system welcomes Dr. Reisner ... experienced physicians comprise CarePoint Health Medical Group, a ... Hudson County, representing a wide range of specialties. ...
(Date:8/22/2014)... NJ. August 22, 2014. A new study ... persons with multiple sclerosis (MS) may be able ... The study was epublished ahead of print on ... Helen Genova, Hali Griswold, Nancy D. Chiaravalloti & ... persons with multiple sclerosis doi: 10.3233/NRE-141113). Self-awareness is ...
(Date:8/22/2014)... NEWPORT, RI Newport Hospital has again attained ... Nurses Credentialing Center,s (ANCC) Magnet Recognition Program. Considered ... hospital credentialing program recognizes nursing excellence and professionalism. ... nursing care. The unanimous decision to redesignate Newport ... to rigorous national standards of nursing practice. , ...
Breaking Medicine News(10 mins):Health News:High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 3Health News:Dr. Reisner Joins CarePoint Health Medical Group 2Health News:Kessler Foundation study of self-awareness in MS has implications for rehabilitation 2Health News:Newport Hospital receives nursing's highest credential for third time with Magnet recognition 2
... released the following statement on President Obama,s nomination of ... of Health and Human Services: "Governor Sebelius is ... health care access for children and to provide Kansans ... health care issues and their impact on our workers ...
... Aflac Incorporated (NYSE: AFL ) announced today that ... Annual Institutional Investors Conference. Sr. Vice President of Investor Relations ... is scheduled to make a presentation on March 9 at ... Janke will discuss the company,s outlook for 2009 and its ...
... March 2 Did you know that in ... five times more often and is six times ... are more eye-opening facts to share about this ... at: http://inr.mediaseed.tv/oneClip_C/?feed=pnskfD12vWjRAu2ArGmCrdet11lZRHEf Registered journalists can access video, ...
... A new study in the online issue of ... medications can work well among certain HIV patients who ... at higher risk for cardiovascular disease in part due ... of certain antiretroviral therapies, researchers now have evidence that ...
... week away, study finds, , , MONDAY, March 2 (HealthDay News) ... children with mild persistent asthma begin to show dramatic changes ... March issue of Pediatrics reports that just seven ... for a rural area, airway inflammation went down and lung ...
... cites association on GMPs and adverse event reportingWASHINGTON, ... the U.S. Government Accountability Office (GAO) of a ... supplements, the Natural Products Association (NPA) released the ... Seckman."The Natural Products Association appreciates having the opportunity ...
Cached Medicine News:Health News:Aflac Incorporated To Present at the Raymond James 30th Annual Institutional Investors Conference 2Health News:Largest Study to Date Compares Cholesterol Treatment in HIV Patients & Patients Without HIV Infection 2Health News:Largest Study to Date Compares Cholesterol Treatment in HIV Patients & Patients Without HIV Infection 3Health News:Largest Study to Date Compares Cholesterol Treatment in HIV Patients & Patients Without HIV Infection 4Health News:City Kids Find the Breathin' Is Easier Elsewhere 2Health News:City Kids Find the Breathin' Is Easier Elsewhere 3Health News:Natural Products Association Comments on New GAO Report on Regulation of Dietary Supplements 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: